Comparative Pharmacology
Head-to-head clinical analysis: MYOTONACHOL versus VUITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYOTONACHOL versus VUITY.
MYOTONACHOL vs VUITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.
VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% is a muscarinic receptor agonist. It induces miosis by contracting the iris sphincter muscle, increasing the eye's depth of focus and improving near visual acuity. It acts via the ciliary muscle to reduce the diameter of the pupil, creating a pinhole effect that enhances depth of focus.
25 mg orally three times daily. Maximum dose 100 mg four times daily.
One drop of VUITY (pilocarpine 1.25% ophthalmic solution) instilled into each eye three times daily at approximately 6-8 hour intervals.
None Documented
None Documented
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment).
Terminal half-life: 134 hours (range 110-170 hours). Clinical context: allows once-weekly dosing; steady-state achieved after 2-3 months.
Renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Primarily via hepatic metabolism; inactive metabolites excreted in urine (approximately 90%) and feces (approximately 10%).
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist